Search Results

Business

BlueWind Medical Appoints Lori Chmura as Chair of the Board of Directors

September 16, 2024

·

2 min read

Press Releases

BlueWind Medical Announces Favorable CMS Decision for 2025 Reimbursement Rates for Revi® System’s Implantable Tibial Neuromodulation Therapy

November 4, 2024

·

3 min read

Press Releases

New Research from BlueWind Medical Shows Implantable Tibial Neuromodulation (iTNM), such as the Revi® System, as Effective Alternative to Sacral Neuromodulation (SNM) for Overactive Bladder and Urge Urinary Incontinence

October 31, 2024

·

4 min read

BlueWind Medical Brings Revi™ Implantable Tibial Neuromodulation Device to Patients in Central Ohio

BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Springfield, Ohio at Ohio Valley Surgical Hospital with urologist Dr. Eric Espinosa.

February 7, 2024

·

3 min read

BlueWind Medical’s Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence

BlueWind Medical, Ltd. today announced that the US Food and Drug Administration (FDA) granted a De Novo marketing request for the Revi System, a transformative tibial neuromodulation therapy for the treatment of the symptoms of urgency incontinence alone or in combination with urinary urgency.

August 17, 2023

·

4 min read

Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting

BlueWind Medical, Ltd., the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB.

May 1, 2023

·

4 min read

Business

BlueWind Medical Announces New Executive Appointments

BlueWind Medical, Ltd., a medical device company transforming neuromodulation therapy for overactive bladder, announced three executive appointments to leadership positions within the company.

November 1, 2022

·

4 min read

BioMidwest

BlueWind Medical Announces Key Milestone as AMA Issues Unique Category III CPT Code for Subfascial Placement of Tibial Neurostimulators

BlueWind Medical, Ltd. is pleased to announce that the American Medical Association has issued a new Current Procedural Terminology code for the subfascial implantation of a tibial neuromodulation device for Overactive Bladder.

March 8, 2023

·

4 min read

BlueWind Medical to Present Positive Results from its Pivotal Trial in Patients with Overactive Bladder at the 2023 AUA Annual Meeting

BlueWind Medical, Ltd., the developer of transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced that efficacy results of the OASIS pivotal clinical study will be presented in a late breaking session at the American Urological Association (AUA) 2023 Annual Meeting, being held in Chicago April 27th- May 1st.

April 24, 2023

·

3 min read

Business

BlueWind Medical Appoints Dr. Liz Kwo to Board of Directors

BlueWind Medical, Ltd. announced that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company’s Board of Directors.

September 27, 2022

·

3 min read